HPV Positive Oropharyngeal Squamous Cell Carcinoma Clinical Trials

13 recruiting

HPV Positive Oropharyngeal Squamous Cell Carcinoma Trials at a Glance

14 actively recruiting trials for hpv positive oropharyngeal squamous cell carcinoma are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 2 with 11 trials, with the heaviest enrollment activity in New York, New Brunswick, and Commack. Lead sponsors running hpv positive oropharyngeal squamous cell carcinoma studies include Christian Hinrichs, Memorial Sloan Kettering Cancer Center, and Jonathan Schoenfeld, MD, MPH.

Browse hpv positive oropharyngeal squamous cell carcinoma trials by phase

Treatments under study

About HPV Positive Oropharyngeal Squamous Cell Carcinoma Clinical Trials

Looking for clinical trials for HPV Positive Oropharyngeal Squamous Cell Carcinoma? There are currently 13 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HPV Positive Oropharyngeal Squamous Cell Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HPV Positive Oropharyngeal Squamous Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 2

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

HPV-Related MalignancyHPV-Related CarcinomaHPV Positive Oropharyngeal Squamous Cell Carcinoma+2 more
Memorial Sloan Kettering Cancer Center30 enrolled8 locationsNCT05307939
Recruiting
Phase 1Phase 2

TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

Head and Neck CancerHPV Positive Oropharyngeal Squamous Cell CarcinomaHuman Papilloma Virus+1 more
University of Chicago98 enrolled1 locationNCT05108870
Recruiting
Phase 1Phase 2

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Cervical CancerAnal CancerPenile Cancer+14 more
Christian Hinrichs15 enrolled2 locationsNCT05639972
Recruiting
Phase 2

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Cervical CancerMetastatic CancerAnal Cancer+18 more
Christian Hinrichs20 enrolled3 locationsNCT05686226
Recruiting
Phase 2

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

Squamous Cell Carcinoma of Head and NeckOral Cavity CancerNasal Cavity Cancer+9 more
Memorial Sloan Kettering Cancer Center40 enrolled7 locationsNCT07063212
Recruiting
Phase 1Phase 2

A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer

HPV-Related Cervical CarcinomaHPV Positive Oropharyngeal Squamous Cell Carcinoma
Theravectys S.A.72 enrolled4 locationsNCT06319963
Recruiting
Phase 2

Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma

HPV Positive Oropharyngeal Squamous Cell CarcinomaOropharyngeal Carcinoma
NYU Langone Health120 enrolled1 locationNCT03215719
Recruiting
Phase 2

Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)

Head and Neck CancerHead and Neck Squamous Cell CarcinomaHPV Positive Oropharyngeal Squamous Cell Carcinoma+2 more
University of Maryland, Baltimore61 enrolled5 locationsNCT06088381
Recruiting
Phase 2

Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study

HPV Positive Oropharyngeal Squamous Cell CarcinomaHPV-Related Squamous Cell CarcinomaClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8+9 more
Jonathan Schoenfeld, MD, MPH145 enrolled2 locationsNCT04900623
Recruiting
Not Applicable

De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE)

HPV Positive Oropharyngeal Squamous Cell Carcinoma
Royal North Shore Hospital25 enrolled1 locationNCT06307015
Recruiting

De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx

HPV Positive Oropharyngeal Squamous Cell Carcinoma
University of California, Irvine111 enrolled1 locationNCT05600842
Recruiting
Phase 1Phase 2

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

HNSCCHPV Positive Oropharyngeal Squamous Cell Carcinoma
Nykode Therapeutics ASA51 enrolled17 locationsNCT06016920
Recruiting
Phase 2

Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer

HPV Positive Oropharyngeal Squamous Cell CarcinomaOropharynx CancerThroat Carcinoma+1 more
University of Missouri-Columbia28 enrolled1 locationNCT04444869
Recruiting
Phase 3

TROG 12.01 A Randomised Trial of Weekly Cetuximab and Radiation versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma

HPV positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Trans-Tasman Radiation Oncology Group200 enrolled17 locationsACTRN12613000279729